The subscription price for the exercise of warrants of series TO 3 in Dicot AB has been set to 0.29 SEK per share

29 May 2022 - 21:00

Press release: Uppsala, May 29, 2022.

During the fourth quarter of 2021, Dicot AB (publ) (``Dicot`` or ``the Company``) conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3 (previously also named series 2021/2022). Those who subscribed for units during the subscription period between October 12, 2021, and October 27, 2021, therefore obtained three (3) additional warrants of series TO 3 per unit subscribed. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in Dicot. The subscription price for subscription of shares using warrants will correspond to 70 percent of the average volume-weighted price of the Company's share according to Spotlight Stock market's official list during the period from May 16, 2022, up to and including May 27, 2022. However, the subscription price shall not be higher than 1.50 SEK or lower than 0.125 SEK (corresponding quota value of the Company's share). The average volume-weighted price of the Company’s share during the measurement period amounted to approximately 0.41 SEK, hence, the subscription price has been set to 0.29 SEK per share.

Terms for the warrants of series TO 3 in short:

One (1) warrant of series TO 3 entitles the owner to subscribe for one (1) new share in the Company.

Subscription price: 0.29 SEK per new issued share.

Volume: 38 068 461 warrants of series TO 3. If fully exercised, 38 068 461 new shares are issued, and the Company will receive approximately 11.0 MSEK before transaction costs.

Subscription period: June 1, 2022 – June 15, 2022.

Trading with warrants of series TO 3: Warrants of series TO 3 can be traded at Spotlight Stock Market under the ticker ``DICOT TO 3`` with ISIN-code SE0016844450. Last day of trading with warrants of series TO 3 is June 13, 2022.

Note that the warrants that are not used to subscribe for new shares, or are sold in the market before June 13, 2022, or are used for subscription at latest June 15, 2022, will expire and thus lose their value. To ensure that the warrant owner’s warrants of series TO 3 don’t expire without value the owner has to actively subscribe for shares or sell their warrants in the market. Note that some trustees may close the subscription period prematurely.

Complete terms for the warrants of series TO 3 was included in the prospectus regarding the rights issue of units released on September 8, 2021. An independent document with complete terms for the warrants of series TO 3 as well as the prospectus is available at the above-mentioned web address.

How to use the warrants:

Trustee registered warrants (Custody account)

Subscription and payment with the use of warrants of series TO 3 shall be made in accordance with instructions from each trustee. If you have further questions regarding subscription and payment please contact your trustee for additional information in good time before June 15, 2022, as different trustees may have different processing times.

Directly registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The application for must be filled out and delivered to the issuing agent Hagberg & Aneborn Fondkommission AB as of latest 15:00 on June 15, 2022

The warrants will then be replaced by interim shares (IS) awaiting registration at the Swedish Companies Registration Office.

The subscription form will be available at the Company’s homepage,, and on Hagberg & Aneborn Fondkommission´s homepage


Stockholm Corporate Finance AB acted as the financial adviser and Advokatfirman Lindahl KB as legal adviser regarding the Units issue during the fourth quarter 2021, and acts in the in the same capacity regarding the subscription of warrants of series TO 3. Hagberg & Aneborn Fondkommission AB acts as issuing agent regarding the warrants of series TO 3.

For questions regarding the warrants, please contact:
Hagberg & Aneborn Fondkommission AB 
Phone: + 46 (0) 840 89 33 50 

E-mail: [email protected] 

For additional questions regarding the warrants, please contact:
Elin Trampe, CEO
Phone: +46 (0) 739 80 14 08
E-mail: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit

About Stockholm Corporate Finance AB

Stockholm Corporate Finance AB is a Swedish, independent and privately-owned financial advisor which offers financial advisory by taking transaction activities, acting in an advisory capacity and assisting with transaction process implementation, working closely with the owners, board members and management in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which consists of 49 M&A advisors and investment banks in 36 countries. SCF is under the supervision of the Swedish Financial Supervisory Authority, Finansinspektionen, and is also a member of the industry-organization SwedSec Licensiering AB. For more information:

Provided by: Cision
Spotlight Stock Market (Sweden)
Dicot AB
Dicot is a pharmaceutical company with focus on the development of pharmaceuticals for the treatment of various sexual dysfunctions. The products are sold under various trademarks, and primarily treat erection problems among men. The main substance is formed from libiguin, a substance from the root of a particular tree found on Madagascar....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More